2021
Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. European Respiratory Journal 2021, 58: 2100759. PMID: 34531276, PMCID: PMC8613836, DOI: 10.1183/13993003.00759-2021.Peer-Reviewed Original ResearchConceptsEfficacy of nintedanibIdiopathic pulmonary fibrosisAged miceLung fibrosisPulmonary fibrosisElderly patientsLung functionPre-clinical efficacy studiesAged animal modelsIPF clinical trialsVital capacity declineAverage patient ageVehicle-treated miceVehicle-treated groupEffect of nintedanibSeverity of fibrosisDevelopment of fibrosisTotal lung collagenSimilar extentNintedanib treatmentLung injuryPatient ageIPF diagnosisClinical efficacyFibrosis severity
2015
Role of macrophage migration inhibitory factor in age-related lung disease
Sauler M, Bucala R, Lee PJ. Role of macrophage migration inhibitory factor in age-related lung disease. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2015, 309: l1-l10. PMID: 25957294, PMCID: PMC4491511, DOI: 10.1152/ajplung.00339.2014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMacrophage migration inhibitory factorAge-related lung diseaseMigration inhibitory factorLung diseaseInhibitory factorChronic obstructive lung diseaseChronic lung diseaseObstructive lung diseaseCommon respiratory disorderPulmonary fibrosisClinical manifestationsProinflammatory cytokinesLung cancerRespiratory disordersImmune systemVariant allelesDiseaseHost factorsSuch diseasesPotent upstream regulatorUpstream regulatorPneumoniaFibrosisBody of literatureCytokines